M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
Open accessAbstract
Tumors evade host immune surveillance through multiple mechanisms, including the generation of a tumor microenvironment that suppresses immune effector function. Secretion of TGFβ and upregulation of immune checkpoint programmed cell death ligand-1 (PD-L1) are two main contributors to immune evasion and tumor progression. Here, we examined the efficacy of a first-in-class bifunctional checkpoint inhibitor, the fusion protein M7824, comprising the extracellular domain of human TGFβRII (TGFβ Trap) linked to the C-terminus of human anti-PD-L1 heavy chain (αPD-L1). We demonstrate that M7824 reduces plasma TGFβ1, binds to PD-L1 in the tumor, and decreases TGFβ-induced signaling in the tumor microenvironment in mice. In murine breast and colon carcinoma models, M7824 decreased tumor burden and increased overall survival as compared to targeting TGFβ alone. M7824 treatment promoted CD8+ T cell and NK cell activation, and both of these immune populations were required for optimal M7824-mediated tumor control. M7824 was superior to TGFβ- or αPD-L1-targeted therapies when in combination with a therapeutic cancer vaccine. These findings demonstrate the value of using M7824 to simultaneously target TGFβ and PD-L1/PD-1 immunosuppressive pathways to promote anti-tumor responses and efficacy. The studies also support the potential clinical use of M7824 as a monotherapy or in combination with other immunotherapies, such as therapeutic cancer vaccines, including for patients who have progressed on αPD-L1/αPD-1 checkpoint blockade therapies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Antibodies against integrins β1, β6 and β8 selectively impair TGF-β1 activation.
“Antibodies against integrins β1, β6 and β8 were shown to selectively impair TGF-β1 activation85,313–315”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
RETRACTED: FoxP3 Acts as a Cotranscription Factor with STAT3 in Tumor-Induced Regulatory T Cells
Hossain, D. M. S., Panda, A. K., Manna, A., Mohanty, S., Bhattacharjee, P., Bhattacharyya, S., Saha, T., Chakraborty, S., Kar, R. K., Das, T., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.005 · Cited by 114 · see citing works
RetractedThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907 · see citing works
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · see citing works
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · see citing works
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,382 · see citing works
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355 · see citing works
TGFβ: the molecular Jekyll and Hyde of cancer
Bierie, B., & Moses, H. L. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1926 · Cited by 1,262 · see citing works
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · see citing works
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236 · see citing works
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,178 · see citing works
Shang, B., Liu, Y., Jiang, S.-J., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep15179 · Cited by 985 · see citing works
The roles of TGFβ in the tumour microenvironment
Pickup, M. W., Novitskiy, S. V., & Moses, H. L. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3603 · Cited by 915 · see citing works
Pulaski, B. A., & Ostrand‐Rosenberg, S. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2002s39 · Cited by 912 · see citing works
TGF-β Activation and Function in Immunity
Travis, M. A., & Sheppard, D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120257 · Cited by 856 · see citing works
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 820 · see citing works
Castriconi, R., Cantoni, C., Chiesa, M. D., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 727 · see citing works
Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and InfectionPreprint
Sanjabi, S., Oh, S. A., & Li, M. O. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022236 · Cited by 626 · see citing works
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585 · see citing works
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 550 · see citing works
TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
Principe, D. R., Doll, J. A., Bauer, J. I., Jung, B., Munshi, H. G., Bartholin, L., Pasche, B., Lee, C., & Grippo, P. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt369 · Cited by 523 · see citing works
Yu, P., Lee, Y., Liu, W., Krausz, T. N., Chong, A. S., Schreiber, H. W., & Fu, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041684 · Cited by 433 · see citing works
Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease.
Kopp, J. B., Factor, V. M., Mozes, M., Nagy, P., Sanderson, N., Böttinger, E. P., Klotman, P. E., & Thorgeirsson, S. S. (1996) · PubMed · Cited by 422 · see citing works
Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406 · see citing works
Self-citationImproved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008211 · Cited by 383 · see citing works
The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis
Neel, J.-C., Humbert, L., & Lebrun, J. J. (2012) · ISRN Molecular Biology · doi:10.5402/2012/381428 · Cited by 353 · see citing works
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi‐Ferchiou, A., Lambert, M., Dogniaux, S., Vely, F., Vivier, É., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312 · see citing works
Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., Zlabinger, G. J., Steinberger, P., Pickl, W. F., Stockinger, H. S. J., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.7.3637 · Cited by 261 · see citing works
Targeting TGF-β Signaling for Therapeutic GainPreprint
Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 243 · see citing works
Postow, M. A., Manuel, M., Wong, P., Yuan, J., Dong, Z., Liu, C., Perez, S., Tanneau, I., Noel, M., Courtier, A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0070-4 · Cited by 232 · see citing works
A twist for survival and cancer progression
Puisieux, A., Valsesia‐Wittmann, S., & Ansieau, S. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602876 · Cited by 223 · see citing works
David, J. M., Dominguez, C., McCampbell, K. K., Gulley, J. L., Schlom, J., & Palena, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349589 · Cited by 180 · see citing works
Self-citationUpregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer
Qing, Y., Li, Q., Ren, T., Xia, W., Peng, Y., Liu, G. L., Luo, H., Yang, Y., Dai, X. Y., Zhou, S., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s75152 · Cited by 178 · see citing works
TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation
Zhang, N., & Bevan, M. J. (2012) · Nature Immunology · doi:10.1038/ni.2319 · Cited by 175 · see citing works
Moo‐Young, T. A., Larson, J. W., Belt, B. A., Tan, M. C. B., Hawkins, W. G., Eberlein, T. J., Goedegebuure, P. S., & Linehan, D. C. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318189f13c · Cited by 165 · see citing works
Robbins, P. F., Kantor, J. A., Salgaller, M. L., et al. (1991) · PubMed · Cited by 150 · see citing works
Differential regulation of TGF-β signaling through Smad2, Smad3 and Smad4
Kretschmer, A., Moepert, K., Dames, S., Sternberger, M., Kaufmann, J., & Klippel, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206791 · Cited by 143 · see citing works
Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Gulley, J. L., Madan, R. A., Tsang, K. Y., Jochéms, C., Marté, J. L., Farsaci, B., Tucker, J. A., Hodge, J. W., Liewehr, D. J., Steinberg, S. M., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0108 · Cited by 136 · see citing works
Self-citationUngefroren, H., Groth, S., Sebens, S., Lehnert, H., Gieseler, F., & Fändrich, F. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-67 · Cited by 128 · see citing works
Bacman, D., Merkel, S., Croner, R. S., Papadopoulos, T., Brueckl, W. M., & Dimmler, A. W. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-156 · Cited by 118 · see citing works
Kim, I. Y., Ahn, H. J., Lang, S., Oefelein, M. G., Oyasu, R., Kozlowski, J. M., & Lee, C. (1998) · PubMed · Cited by 114 · see citing works
Chen, J., Heldman, M. R., Herrmann, M. A., Kedei, N., Woo, W., Blumberg, P. M., & Goldsmith, P. K. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.07.022 · Cited by 99 · see citing works
Self-citationLiu, L., Liu, X., Ren, X., Tian, Y., Chen, Z., Xu, X., Du, Y., Jiang, C., Fang, Y., Liu, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep21602 · Cited by 95 · see citing works
Terabe, M., Robertson, F. C., Clark, K. T., Ravin, E. D., Bloom, A. C., Venzon, D. J., Kato, S., Mirza, A. M., & Berzofsky, J. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1308616 · Cited by 89 · see citing works
Hawinkels, L. J. A. C., Verspaget, H. W., van Duijn, W., Zon, J. M. V. D., Zuidwijk, K., Kubben, F. J. G. M., Verheijen, J. H., Hommes, D. W., Lamers, C. B. H. W., & Sier, C. F. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603877 · Cited by 86 · see citing works
Henriksen, R., Gobl, A., Wilander, E., et al. (1995) · PubMed · Cited by 84 · see citing works
Kudo‐Saito, C., Schlom, J., & Hodge, J. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1380 · Cited by 78 · see citing works
Self-citationGain or loss of TGF-β signaling in mammary carcinoma cells can promote metastasis
Bierie, B., & Moses, H. L. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9727 · Cited by 60 · see citing works
Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
Jochéms, C., Tritsch, S. R., Pellom, S. T., Su, Z., Soon‐Shiong, P., Wong, H. C., Gulley, J. L., & Schlom, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20680 · Cited by 55 · see citing works
Self-citationFlanders, K. C., Yang, Y.-A., Herrmann, M., Chen, J., Mendoza, N., Mirza, A. M., & Wakefield, L. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9416 · Cited by 39 · see citing works
Self-citationArdiani, A., Gameiro, S. R., Palena, C., Hamilton, D. H., Kwilas, A. R., King, T. H., Schlom, J., & Hodge, J. W. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2045 · Cited by 38 · see citing works
Self-citationHu, J., Zhu, S., Xia, X., Zhang, L., Kleinerman, E. S., & Li, S. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-34 · Cited by 37 · see citing works
Kwilas, A. R., Ardiani, A., Dirmeier, U., Wottawah, C. M., Schlom, J., & Hodge, J. W. (2015) · Oncotarget · doi:10.18632/oncotarget.4442 · Cited by 27 · see citing works
Self-citationAdam, A. J. M., Felcher, A. H., Woods, M. L., et al. (1994) · Journal of Immunotherapy · doi:10.1097/00002371-199404000-00001 · Cited by 26 · see citing works
The Role of Transcription Factor TWIST in Cancer Cells
Je, E. C. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000124 · Cited by 24 · see citing works
Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction
Andre, M. C., Sigurdardottir, D., Kuttruff, S., Pömmerl, B., Handgretinger, R., Rammensee, H., & Steinle, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26191 · Cited by 23 · see citing works
TCR diversity – a universal cancer immunotherapy biomarker?
McNeel, D. G. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0175-4 · Cited by 21 · see citing works
Keystone symposia on molecular and cellular biology
(1994) · FEMS Microbiology Reviews · doi:10.1016/0168-6445(94)90028-0 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works
Combination strategies to maximize the benefits of cancer immunotherapy
Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01164-5 · Cited by 654 · see citing works
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413 · see citing works
“The combination of an adenovirus cancer vaccine encoding tumor-associated antigen TWIST1 (Ad-TWIST) and bifunctional fusion protein M7824 that targets both TGFβ and PD-L1 displayed superior improvement of the antitumor efficacy as compared to Ad-TWIST monotherapy in multiple murine models of human solid tumors.(310) I…”
BackgroundCommunication between EMT and PD-L1 signaling: New insights into tumor immune evasion
Jiang, Y., & Zhan, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.013 · Cited by 319 · see citing works
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256 · see citing works
Hammerl, D., Martens, J. W. M., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., Isaeva, O. I., Voorwerk, L., Balcioglu, H. E., Wijers, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25962-0 · Cited by 262 · see citing works
Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247 · see citing works
Self-citationThe efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108707 · Cited by 236 · see citing works
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133 · see citing works
Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119 · see citing works
Product review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91 · see citing works
Metropulos, A. E., Munshi, H. G., & Principe, D. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104380 · Cited by 81 · see citing works
Hicks, K. C., Chariou, P. L., Ozawa, Y., Minnar, C. M., Knudson, K. M., Meyer, T. J., Bian, J., Cam, M., Schlom, J., & Gameiro, S. R. (2021) · Nature Communications · doi:10.1038/s41467-021-25393-x · Cited by 83 · see citing works
Self-citationHicks, K. C., Knudson, K. M., Lee, K. L., Hamilton, D. H., Hodge, J. W., Figg, W. D., Ordentlich, P., Jones, F. R., Rabizadeh, S., Soon-Shiong, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0727 · Cited by 44 · see citing works
Self-citation
- Authors
- Knudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Schlom, Jeffrey
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2018-02-14
- Volume
- 7
- Issue
- 5
- Pages
- e1426519
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5927523
- OpenAlex
- W2783653336
- Cited by
- 195
- References
- 64
- Citations by year
- 2026: 12 · 2025: 11 · 2024: 15 · 2023: 26 · 2022: 29 · 2021: 38 · 2020: 29 · 2019: 22 · 2018: 12
- FWCI
- 9.49
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-02-27)
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- OncoImmunology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cooperative Research and Development Agreement between the National Cancer Institute and EMD Serono, Inc. (CRADA 02666)
- Intramural Research Program, CCR, NCI, NIH (ZIA BC 010944)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- bifunctional fusion protein, PD-L1 inhibitors, TGF-βRII, TGF-β1, PD-L1, immune checkpoint blockade, tumor microenvironment, tumor immune evasion, therapeutic cancer vaccines, combination immunotherapy, CD8+ T cells, natural killer cells, breast cancer, colon cancer, antitumor immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
